Where HEOR Program Spend Accumulates
At $1M–$8M per indication, HEOR programs carry significant CRO engagement costs. Much of that spend covers work that is highly structured: updating Markov model parameter inputs when new RWE studies publish, reformatting outputs into ISPOR-compliant formats, and populating AMCP dossier sections from model outputs and clinical summaries. When these workflows run through Excel hand-offs and HEOR team email chains, the turnaround from new evidence to updated model to dossier section is measured in weeks — and each delay pushes payer submission timelines out.
How the Agent Closes the Evidence-to-Dossier Gap
An AI Labor Company agent monitors budget-impact model and cost-effectiveness model update workflows from HEOR team emails and Excel hand-offs. When new RWE studies are identified, the agent refreshes Markov model parameter inputs in ISPOR format and auto-populates the relevant AMCP dossier sections. The Health Economics Director reviews and approves model assumptions before any material goes to payers — the agent handles the mechanics of parameter identification, model refresh, and dossier assembly; the human validates the science. Deployment typically runs about twelve weeks. Teams in this position can expect to reach operational deployment with time to spare before the next major payer engagement cycle.
The Business Case: CRO Cost Recovery and Faster Market Access
Reducing CRO HEOR project spend by an illustrative 40% per indication is a direct cost recovery story, but the more important lever is speed. When the evidence-to-dossier cycle compresses, formulary review submissions happen earlier in the payer calendar, and earlier submissions translate to faster formulary placement and revenue recognition. The agent handling 45–65% of the model update and dossier population workload also means the HEOR team can manage more indications in parallel without scaling the CRO relationship proportionally — a capacity benefit that compounds as the pipeline grows.
Does the agent modify the underlying Markov model structure, or only the parameters?
The agent updates parameter inputs — transition probabilities, cost inputs, utility values — based on newly published RWE studies. Model structure changes require Health Economics Director review and approval as a separate workflow.
Which AMCP dossier sections does the agent populate?
The agent auto-populates sections that map directly to model outputs and clinical evidence summaries, including budget impact tables and cost-effectiveness results. Sections requiring original narrative judgment are flagged for human authorship.